New drug duo aims to wipe out bladder tumors before surgery
NCT ID NCT07624201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs (trastuzumab rezetecan and adebrelimab) before surgery can eliminate or shrink tumors in people with a specific type of muscle-invasive bladder cancer (HER2-positive). About 58 adults will receive the combination, then have their bladder removed to check for remaining cancer. The goal is to see if this approach leads to a complete response (no cancer found).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- Bladder preservation: a viable alternative to radical surgery?
- New bladder cancer combo shows promise in Pre-Surgery trial
- Promising combo aims to shrink bladder tumors before surgery
- Which scan is better for bladder cancer staging? new study aims to find out
- Microscopic clues may forecast bladder Cancer's next move